Physician
Endocrinology
Dr. Naifa L. Busaidy, MD
|
|
Give Review
Doctor Naifa L. Busaidy, MD practices Endocrinology. He researched medicine at Baylor College of Medicine. He has 1 awards "Fellow (FACE)". Naifa L. Busaidy, MD is a published doctor as well. He has 40 publications published. The latest was: Preexisting adrenal masses in patients with adrenocortical carcinoma: clinical and radiological factors contributing to delayed diagnosis. He accepts all Medicare patients.
Publications
- Preexisting Adrenal masses in patients with adrenocortical carcinoma: clinical and radiological factors contributing to delayed diagnosis.
- Efficacy and tolerability of vemurafenib in patients with BRAF(V600E) -positive papillary Thyroid cancer: M.D. Anderson Cancer Center off label experience.
- Role of salvage targeted therapy in differentiated Thyroid cancer patients who failed first-line sorafenib.
- Efficacy and Tolerability of Different Starting Doses of Sorafenib in Patients With Differentiated Thyroid Cancer.
- Measuring the Extent of Total Thyroidectomy for Differentiated Thyroid Carcinoma Using Radioactive Iodine Imaging: Relationship With Serum Thyroglobulin and Clinical O...
- Prevalence by Age and Predictors of Medullary Thyroid Cancer in Patients with Lower Risk Germline RET Proto-Oncogene Mutations.
- Spindle Epithelial Tumor with Thymus-like Differentiation (SETTLE): A Case Report and Comprehensive Review of the Literature and Treatment Options.
- Current update on medullary Thyroid carcinoma.
- Sorafenib suppresses JNK-dependent apoptosis through inhibition of ZAK.
- Adrenocortical carcinoma: Clinical outcomes and prognosis of 330 patients at a tertiary care center.
- Adrenal Ganglioneuroma: Features and outcomes of 27 cases at a referral cancer center.
- The biopsy-proven benign Thyroid nodule: is long-term follow-up necessary?
- Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary Thyroid carcinoma on long-term RET inhibitor therapy.
- The Noninvestigational Use of Tyrosine Kinase Inhibitors in Thyroid Cancer: Establishing a Standard for Patient Safety and Monitoring.
- Older patients with primary hyperparaThyroidism have greater than age predicted functional deficits.
- A Randomized Controlled Trial of an Intensive Insulin Regimen in Patients With Hyperglycemic Acute Lymphoblastic Leukemia.
- Phase I trial of cixutumumab combined with temsirolimus in patients with advanced Cancer.
- Inhibition of the Ras/Raf/MEK/ERK and RET Kinase Pathways with the Combination of the Multikinase Inhibitor Sorafenib and the Farnesyltransferase Inhibitor Tipifarnib ...
- Random postoperative day 3 cortisol as a predictor of hypothalamic-pituitary-Adrenal axis integrity after transsphenoidal surgery.
- Cushing syndrome secondary to ectopic adrenocorticotropic hormone secretion: the University of Texas MD Anderson Cancer Center Experience.
- Cystic lymph nodes in the lateral neck as indicators of metastatic papillary Thyroid cancer.
- Challenges associated with tyrosine kinase inhibitor therapy for metastatic Thyroid cancer.
- Treatment with tyrosine kinase inhibitors for patients with differentiated Thyroid cancer: the M. D. Anderson experience.
- ParaThyroidectomy improves functional capacity in "asymptomatic" older patients with primary hyperparaThyroidism: a randomized control trial.
- Clinical significance of distinguishing between follicular lesion and follicular neoplasm in Thyroid fine-needle aspiration biopsy.
- Growth factor receptors expression in anaplastic Thyroid carcinoma: potential markers for therapeutic stratification.
- ParaThyroid carcinoma: a 22-year experience.
- Nasolacrimal duct obstruction associated with radioactive iodine therapy for Thyroid carcinoma.
- A catecholamine crisis on Mount Kilimanjaro: a hypoxia effect?
- Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor locat...
- Phase I clinical trials in 56 patients with Thyroid cancer: the M. D. Anderson Cancer Center experience.
- Follow-up of low-risk differentiated Thyroid cancer patients who underwent radioiodine ablation of postsurgical Thyroid remnants after either recombinant human thyrotr...
- Prospective, randomized, controlled trial of paraThyroidectomy versus observation in patients with "asymptomatic" primary hyperparaThyroidism.
- Diabetes mellitus among cancer survivors.
- A novel nomenclature to classify paraThyroid adenomas.
- Assessment of the incremental value of recombinant thyrotropin stimulation before 2-[18F]-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography ima...
- Radioiodine ablation of Thyroid remnants after preparation with recombinant human thyrotropin in differentiated Thyroid carcinoma: results of an international, randomi...
- Phase II study of celecoxib in metastatic differentiated Thyroid carcinoma.
- Unilateral renal artery stenosis with renal atrophy in a patient with metastatic papillary Thyroid carcinoma treated with sorafenib.
Schools
Baylor Coll Of Med
Conditions Treated
- Abnormal Thyroid
- Adrenal Incidentaloma
- Calcium Metabolism Disorders
- Diabetes Insipidus
- View All
Doctors Specialties
- Endocrinology
Accepted Insurances
- Choice Plus POS II
- Blue Card PPO
- Blue Choice
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- LocalPlus
- Open Access Plus
- First Health (Coventry Health Care) PPO
- Choice Care PPO
- MultiPlan PPO
- PHCS Network PPO
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
Awards
- Fellow (FACE)
Education
-
Baylor College of Medicine
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1427144161 | |
| NPPES Provider LastName | BUSAIDY | |
| NPPES Provider FirstName | NAIFA | |
| NPPES Provider ZIPCode | 770304009 | |
| NPPES Provider State | TX | |
| Specialty Description | Endocrinology | |
| Total Claim Count | 520.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1427144161 |
| Last Name Of The Provider | BUSAIDY |
| First Name Of The Provider | NAIFA |
| View All |
Similar Doctors
|
Dr. Ridha Arem, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James L. Pool, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Glenn R. Cunningham, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Tiana M. Shiver, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rocio A. Cordero, MD
This Doctor is OpenDoctor Recommended.
|